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Expansion of different 
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asthmatics
Juan José Nieto-Fontarigo  1, Francisco Javier Salgado  1, María Esther San-José2, 
María Jesús Cruz3,4, Luis Valdés5,6,7, Amparo Pérez-Díaz8, Pilar Arias1, Montserrat Nogueira1 & 
Francisco Javier González-Barcala  4,5,6,7
CD26 displays variable levels between effector (TH17 ≫ TH1 > TH2 > Treg) and naïve/memory 
(memory > naïve) CD4+ T lymphocytes. Besides, IL-6/IL−6R is associated with TH17-differentiation 
and asthma severity. Allergic/atopic asthma (AA) is dominated by TH2 responses, while TH17 immunity 
might either modulate the TH2-dependent inflammation in AA or be an important mechanism boosting 
non-allergic asthma (NAA). Therefore, in this work we have compared the expression of CD26 and 
CD126 (IL-6Rα) in lymphocytes from different groups of donors: allergic (AA) and non-allergic (NAA) 
asthma, rhinitis, and healthy subjects. For this purpose, flow cytometry, haematological/biochemical, 
and in vitro proliferation assays were performed. Our results show a strong CD26-CD126 correlation 
and an over-representation of CD26− subsets with a highly-differentiated effector phenotype in AA 
(CD4+CD26−/low T cells) and NAA (CD4−CD26− γδ-T cells). In addition, we found that circulating levels of 
CD26 (sCD26) were reduced in both AA and NAA, while loss of CD126 expression on different leukocytes 
correlated with higher disease severity. Finally, selective inhibition of CD26-mRNA translation led to 
enhanced T cell proliferation in vitro. These findings support that CD26 down-modulation could play a 
role in facilitating the expansion of highly-differentiated effector T cell subsets in asthma.
Asthma is a heterogeneous disease with different phenotypes (e.g. allergic asthma/AA and non-allergic asthma/
NAA) and endotypes that remain poorly understood1–4. The major endotype classification of asthma is based on 
the predominant T helper (TH)-type inflammation5. On the one hand, TH2high asthma is the most common endo-
type, characterised by an eosinophilic and TH2-driven inflammation and a central role for IgE1,6. On the other 
hand, TH2low asthma is more heterogeneous, including neutrophilic and paucygranulocytic inflammation and 
an involvement of TH1 and TH17 cells1,6. TH17 cells have been associated with asthma severity7,8. Indeed, IL-17 
has been implicated in steroid resistance, airway remodeling, and the induction of neutrophilic inflammation9,10.
In 2012, Bengsch et al. highlighted the use of CD26 as a marker for human TH17 cells11. Moreover, they showed 
that the expression of CD26 amongst Teff cells is variable (TH17 ≫ TH1 > TH2)11, while our group described this 
molecule as a negative selection marker for regulatory T cells (Treg cells)12. CD26/Dipeptidyl peptidase 4 (DPP4) 
is a “moonlighting” protein: it is an enzyme that inactivates important soluble factors (e.g. cytokines like IL-3; 
chemokines like CCL11/Eotaxin or CCL5/RANTES; incretins) and also a protein with proteolytic-independent 
roles (e.g. co-stimulation)13–15. Furthermore, CD26high TH lymphocytes are considered memory16,17 or activated 
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cells18, which explains the presence of CD26highCD4+ T cells in AA19,20. A soluble version of CD26 (sCD26) has 
been found in the bloodstream as a free or a vesicle-associated protein [http://www.exocarta.org]21. Our previ-
ous in vitro studies evidenced a positive correlation between soluble DPP4 activity (an indirect measurement 
of sCD26) and CD26 expression on CD4+ cells20. Immune cells also appear to be a source of sCD26 in vivo15. 
However, contrary to our expectations, allergic asthmatics displayed higher membrane expression of CD26 on 
CD4+ T cells, but decreased levels of sCD26. This finding can be explained through the expansion of a “triple low” 
(Tlow; CD25−CD127−CD26−/low) subpopulation of effector T cells (Teff)20.
IL-6 is an important cytokine in the differentiation of TH17 cells that acts via IL-6R (IL-6Rα/CD126 + gp130)22. 
In this sense, this cytokine down-modulates the TGF-β-driven expression of FoxP3 and up-regulates the levels 
of the transcription factor that controls the development of Th17 cells: RORγt23,24. IL-6 signalling is also essential 
for the generation of functionally active memory CD4+ T cells25. Like CD26, CD126 is also found in plasma as a 
soluble molecule: sIL-6Rα. This circulating protein binds to IL-6 and leads to the activation of CD126−gp130+ 
cells, a process known as trans-signalling26,27. Indeed, CD4+ T cells down-modulate IL-6R upon inflammatory 
activation, but these cells retain the IL-6 response capacity through the trans-signalling pathway28, a mechanism 
of paramount importance for the maintenance of inflammatory diseases such as asthma29–32.
Most research in asthma has been focused on the allergic phenotype and CD4+ T cells. However, CD4− lym-
phocyte subsets (e.g. CD8+ αβ-T cells or γδ-T lymphocytes) might also be relevant for this disease and its phe-
notypes/endotypes. Thus, γδ-T lymphocytes become activated by IL-6 trans-signalling33, and they are important 
inducers of allergic asthmatic responses34. Moreover, they are major initial producers of IL-1735. On the other 
hand, CD8+ T cells cooperate with CD4+ T cells to promote asthma and have been associated with poor lung 
fuction and airway obstruction36–39. Interestingly, the expression of both CD26 and CD126 defines diverse stages 
of differentiation of CD8+ T cells40,41, which might be modified in asthma41. Given this differential expression of 
CD26 and CD126 between different lymphocyte subsets, we postulate that both molecules might display coordi-
nated expression levels and help distinguish different asthma phenotypes. Therefore, the aim of our study was to 
analyse the expression of CD26 and CD126 in CD4+ and CD4− lymphocytes from healthy subjects and patients 
with AA/NAA or rhinitis.
Herein, we report a high correlation between the expression of CD126 and CD26 in lymphocytes. These mole-
cules help differentiate between lymphocytes with naïve (CD26intermediate or CD26int), central-memory (CD26high), 
or “terminally-differentiated” (TEMRA)/effector-memory (TEM) (CD26−/low) phenotypes. Moreover, allergic and 
non-allergic asthmatics display low circulating sCD26 levels, which is consistent with the expansion of CD26−/low 
TEM/TEMRA lymphocytes: CD4+CD26−/low T cells (previously named Tlow cells)20 in AA and CD4−CD26− γδ-T 
cells in NAA. Acceleration of the natural course of CD26 down-modulation on T lymphocytes by siRNA leads 
to higher in vitro proliferation rates, which suggests that CD26 molecules on T lymphocytes could be acting as 
a “brake mechanism” that prevents their proliferation and the acquisition of an effector phenotype. Finally, a 
decrease in the number of CD126 molecules on leukocytes correlates with higher asthma severity. Thus, our 
findings provide new advances in asthma immunophenotyping and on the role of CD26/CD126 in this disease.
Results
Characteristics of study subjects. We performed a case-control study including adult patients with differ-
ent asthma phenotypes (AA; NAA), rhinitis and healthy controls (HC). The characteristics of the donors in this 
study are summarized in Table 1. Pulmonary function parameters (FEV1 and FEV1/FVC) were lower in both AA 
and NAA relative to patients with rhinitis (Table 1). Haematological count revealed an increment of eosinophil 
numbers in asthma patients (both AA and NAA) compared to HC (Table 1). Furthermore, AA displayed higher 
blood eosinophil counts than patients with rhinitis (Table 1). Levels of other leukocyte populations remained 
unchanged (Table 1).
As expected, AA subjects exhibited higher levels of IgE than other study groups (Table 1), and the same hap-
pened for rhinitis compared to NAA (Table 1). Moreover, our results evidenced a reduction of IgG1 in NAA 
relative to AA, while IgG4 was higher in AA vs. R (Table 1). We also analysed the erythrocyte sedimentation rate 
(ESR), which was elevated in NAA vs. remaining groups (Table 1).
CD26 and CD126 molecules display a highly correlated expression on lymphocytes, while 
the expansion of “triple low” (CD25−CD26−CD127−) CD4+ T cells explains the reduction 
of sCD26 in allergic asthma. T cells account for ~80% circulating lymphocytes and include CD4− and 
CD4+ cells. CD4+ lymphocytes (TH) were subdivided into “conventional” Teff (CD25lowCD127high), Treg 
(CD25highCD127low), and Tlow cells (CD25lowCD127low) (Fig. 1a). TH cells displayed the highest percentage of 
CD26+ cells within leukocytes (~85–90%), and this parameter evidenced a positive association with the per-
centage of CD126+ cells (Fig. 1b). Amongst TH lymphocytes, “conventional” Teff (CD26+/high) and especially 
Tlow (CD26−/low) cells exhibited the same high CD26-CD126 correlation, but Tregs appear to lose this associa-
tion (Fig. 1c). Furthermore, we found a reinforced expression of CD26 (measured in Antibody Bound per Cell/
ABC; see Material and Methods section) on CD4+ T cells from AA and NAA patients (Fig. 1d) compared to HC. 
Strikingly, CD126 showed an unaltered expression in CD4+ T cells from the different groups of donors (data not 
shown) despite the strong correlation between CD26 and CD126 commented above (Fig. 1b).
The higher number of CD26 molecules on CD4+ T cells from AA and NAA patients compared to HC (Fig. 1d) 
was in line with the expected activated phenotype of these cells, but contrasted with the decreased levels of 
sCD26 in asthmatics (Fig. 1e). However, as most of sCD26 comes from T cells42, the expansion of CD26−/low T 
lymphocyte populations may explain the decreased levels of sCD26 in AA. Indeed, even though Teff and Treg 
proportions remained unchanged, we detected an expanded subpopulation of CD25−CD127−CD26−/low (Tlow) 
effector T cells in AA patients compared to HC (Fig. 1f). Moreover, contrary to CD4+ and “conventional” Teff 
cells (CD26int/high subsets) and despite the CD26−/low phenotype of these Tlow cells, the percentage of the last 
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subset was negatively correlated with the percentage of CD26+ and CD126+ cells within the Tlow compartment 
(Supplementary Table S1). Interestingly, the percentage of CD127+ Treg cells was augmented in asthmatics com-
pared to rhinitis and HC (Supplementary Fig. S1).
The CD4+CD26−/low T compartment from allergic asthmatics includes memory cells in an 
advanced stage of differentiation. CD26 and CD127 are useful markers for identifying effector/
memory T cells11,16,17. Based on these molecules, CD4+ lymphocytes were segregated in CD26−/low, CD26int, 
and CD26high cells (Fig. 2a). As Fig. 2b illustrates, CD26int and CD26high populations showed elevated expres-
sion of co-stimulatory (CD27, CD28) and lymph node homing (CCR7) molecules, indicating an early dif-
ferentiation stage. In addition, the CD26high subpopulation was mainly composed of CD45RA− cells (i.e. 
central-memory T cells/TCM; CD45RA−CCR7+CD27+CD28+), whereas most of naïve T lymphocytes 
(CD45RA+CCR7+CD27+CD28+) were included within the CD26int subset (Fig. 2b). In contrast, CD26−/low  
lymphocytes showed intermediate levels of CD45RA and a decreased expression of CD27, CD28, CCR7, 
and CD127 molecules (Fig. 2b), which agrees with an advanced differentiation stage (likely TEM or TEMRA, 
CD45RA+CCR7−CD27−CD28−). Moreover, down-modulation of CD27, CD28, and CCR7 was mainly observed 
in CD26−/low cells from patients with moderate-severe AA (Fig. 2c), the group of donors where Tlow cells 
(CD4+CD25−CD127−CD26−/low) were found expanded (Fig. 1f). Apart from Tlow cells, the CD26−/low compart-
ment within the TH subset is also occupied by Treg lymphocytes (CD25highCD127low; Supplementary Fig. S2), 
as Bailey et al. have previously reported17. However, 57.5 ± 7.3% of Treg lymphocytes are also found within the 
AA NAA R HC
N 100 92 44 32
Age (mean (range)) 36 (18–68) 52 (22–72) 35 (18–55) 43 (22–61)
Sex (M/F) 46/54 22/70 25/19 15/17
Disease control
Yes 83 75 44 —
No 17 17 0 —
Baseline treatment
ICS-LABA 79 75 0 0
ICS 16 4 0 0
OCS 1 0 0 0
Antileukotrienes 41 31 11 0
Anticholinergic 15 28 0 0
Roflumilast 0 2 0 0
Prednisone 0 5 0 0
Biochemical, hematological and pulmonary function parameter
FEV1 (%) 97.0 (88.3–107.0)# 97.0 (73.2–112.0)# 108.0 (99.0–119.0) —
FEV1/FVC (%) 76.0 (70.5–80.4)# 73.7 (66.2–80.0)# 83.4 (79.0–87.2) —
Neutrophils (103 cells/μL) 3.70 (3.03–4.29) 3.56 (3.08–4.30) 3.56 (2.89–3.99) 3.02 (2.28–4.05)
Lymphocytes (103 cells/μL) 1.99 (1.67–2.29) 1.94 (1.58–2.34) 2.14 (1.78–2.58) 1.99 (1.53–2.49)
Monocytes (103 cells/μL) 0.40 (0.31–0.47) 0.37 (0.30–0.51) 0.39 (0.31–0.46) 0.39 (0.33–0.49)
Eosinophils (103 cells/μL) 0.29 (0.20–0.47)&# 0.28 (0.16–0.41)& 0.22 (0.14–0.29) 0.13 (0.09–0.22)
Basophils (103 cells/μL) 0.04 (0.03–0.05) 0.03 (0.02–0.05) 0.04 (0.02–0.05) 0.03 (0.02–0.05)
ESR (1 h; mm) 7.5 (4.0–15.0)* 12.0 (7.0–20.8)#& 8.0 (2.0–14.7) 7.5 (2.0–10.0)
TGF-β1 (ng/mL) 14751 (11882–17299) 13712 (10118–18149) 13957 (8691–19056)
15654 (11552–
18620)
sCD25 (ng/mL) 2.86 (2.29–3.64) 3.02 (2.42–3.90) 2.77 (2.29–4.09) 2.77 (2.3–4.13)
IgE (IU/mL) 167.5 (72.0–301.0)*#& 28.0 (10.0–60.5)
# 66.0 (24.0–115.0) 15.0 (5.7–55.7)
IgG (mg/dL) 1075 (943–1200) 1035 (898–1160) 1010 (913–1200) —
IgG1 (mg/dL) 659 (563–745)* 573 (461–677) 617 (530–743) —
IgG2 (mg/dL) 346 (337–429) 337 (263–429) 315 (259–411) —
IgG3 (mg/dL) 33 (23–49) 37 (28–56) 34 (28–48) —
IgG4 (mg/dL) 48 (27–85)# 40 (19–67) 34 (21–51) —
IgA (mg/dL) 226 (167–295) 213 (159–263) 191 (133–274) —
IgM (mg/dL) 98.5 (72–147) 113 (75–151) 111 (69–166) —
TNF (pg/mL) 6.8 (5.5–8.5) 6.2 (5.4–7.6) 6.8 (5.2–9.1) —
Table 1. Characteristics of the study population. AA, allergic asthmatics; HC, healthy controls; NAA, non-
allergic asthmatics; R, rhinitis patients. Data are presented as median value (IQR1–3), unless otherwise 
expressed. Kruskal–Wallis test followed by Dunn’s multiple comparison test (P < 0.05). *AA vs NAA; #asthma 
vs R; &asthma vs HC.
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CD26int subset (Supplementary Fig. S2). In summary, our results evidenced that: (a) most of naïve CD4+ T lym-
phocytes display intermediate expression levels of CD26; (b) The CD26high subpopulation is mainly composed of 
TCM cells; and (c) Tlow cells expanded in AA are likely effector T lymphocytes that have lost CD26 expression to 
become TEM or TEMRA cells (CD27−CD28−CCR7−CD45RA+/−).
Non-allergic asthmatics display increased proportions of CD26−CD127− and CD126−CD127− 
subpopulations amongst CD4− lymphocytes compared to allergic patients. Next, we also 
decided to analyse the population of CD4− lymphocytes (Fig. 3a; left and middle dot plots). This cell compart-
ment is more heterogeneous and includes γδ-T, B, NK, and NKT lymphocytes. Analogously to what happened 
with Tlow cells, the percentage of CD4− lymphocytes was negatively correlated with the percentage of CD26+/
CD126+ cells in this subset (Supplementary Table S1). Moreover, along with the strong correlation between the 
Figure 1. CD26 and CD126/IL-6Rα display a coordinated expression on effector CD4+ T cells, but only CD26/
sCD26 levels are altered in asthma. (a) Gating strategy in flow cytometry assays to identify relevant CD4+ 
T cell subsets. Lymphocytes were gated based on the forward (FSC-Height) and side-scatter (SSC-Height) 
parameters (left dot plot). Then, TH lymphocytes were selected according to their high CD4 expression (middle 
dot plot). Finally, levels of CD25 and CD127 were used to identify three different TH subsets (right dot plot): 
“conventional” Teff cells (Teff), regulatory T cells (Treg), and “triple low” Teff cells (Tlow). (b,c) Correlation 
between the expression (% of positive cells) of CD26 and CD126 on CD4+ (red) or CD4− (blue) lymphocytes 
(b) or within different CD4+ subsets (c): “conventional” Teff (red), Treg (green), and Tlow cells (black) (data 
from all study subjects; N = 268). (d) Expression of CD26 (median ± IQR1-3) presented as number of antibody 
molecules bound per cell (ABC; see Material and Methods section) in healthy controls (HC; N = 32), rhinitis (R; 
N = 44), allergic asthma (AA; N = 100), and non-allergic asthma (NAA; N = 92). (e) Serum levels of sCD26 (ng/
mL) measured by ELISA. (f) Percentage of Tlow cells within the CD4+ T cell gate. (d–f) Statistically significant 
differences between groups are indicated (Kruskal-Wallis test: P < 0.05).
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expression levels of CD26 and CD126 on CD4− lymphocytes (Fig. 1b), we also detected a decreased proportion 
of CD4−CD26+ and CD4−CD126+ cells in NAA compared to AA and R patients (Fig. 3b). Additionally, both 
CD4−CD26+ and CD4−CD126+ cells had a negative correlation with age (rs = −0.482, P < 0.001; rs = −0.508, 
P < 0.001, respectively).
To further characterize CD4− lymphocytes, these cells were subdivided in five subpopulations accord-
ing to CD26 and CD127 levels: CD26int/highCD127−, CD26−CD127−, CD26−CD127+, CD26intCD127+, and 
CD26highCD127+ cells (Fig. 3a). As Fig. 3c shows, we only detected an increment of double negative cells 
(CD26−CD127−) in NAA compared to AA, which was accompanied by a reduction of both CD26intCD127+ and 
CD26highCD127+ lymphocytes. These two last CD4− subsets were rather homogeneous in terms of cell compo-
sition, exhibiting a high proportion (>80–90%) of cytotoxic T cells (Tc; CD3+CD8+) (Fig. 3d). In contrast, the 
composition of CD4−CD26−CD127− lymphocytes was more complex and included Tc, B (CD19+) and CD56+ 
cells (NK, NKT, or γδ-T lymphocytes) (Fig. 3d).
Regarding the CD45RA and CCR7 markers, both CD26+ subpopulations (CD26intCD127+ and 
CD26highCD127+) displayed similar percentages of positive cells (Fig. 3e). Nevertheless, we noticed a decrease of 
CD45RA levels (mean fluorescence intensity/MFI) in CD26high cells (41.4 ± 4.2) compared to the CD26int subset 
(342.1 ± 198.2). This finding supports a differentiation of naïve cells (CD26int) towards a memory-like (CD26high) 
phenotype, compatible with the abundance of co-stimulatory molecules (CD27 and CD28) in both subsets 
(Fig. 3e). In contrast, only a small percentage of CD4−CD26−CD127− cells were CD27+, CD28+, or CCR7+. 
Strikingly, they showed a CD45RAhigh phenotype (Fig. 3e). Altogether, these characteristics define a TEMRA-like 
Figure 2. CD26−/low CD4+ T cells contain effector lymphocytes with an advanced differentiation stage.  
(a) CD4+ T cells were identified by using the same strategy as in Fig. 1a. Then, CD127 and CD26 markers 
were used to delimitate three CD4+ lymphocyte subsets (right dot plot): CD26−/low (including CD127− and 
CD127‘+ cells), CD26int and CD26high. (b) Phenotyping of CD26−/low, CD26int, and CD26high subsets according 
to the surface expression of CD27, CD28, CCR7, CD45RA, and CD127. Data were obtained from 6 donors (3 
healthy subjects and 3 moderate-severe allergic asthmatics) and expressed as % of positive cells for each marker 
(median ± IQR1-3). Kruskal-Wallis test followed by Dunn’s multiple comparison post-hoc analysis was used to 
assess significant changes between groups. *P < 0.05, **P < 0.01, ***P < 0.001. (c) Expression of each marker 
(Percentage of positive cells; median ± IQR1-3) in CD26−/low lymphocytes between healthy subjects (HC; N = 3) 
and moderate-severe allergic asthmatics (MSAA; N = 3). t-test was used to assess significant changes between 
HC and MSAA. *P < 0.05.
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population within CD4−CD26−CD127− lymphocytes. Similar results were obtained when CD4− lymphocytes 
were segregated based on CD126 vs CD127 levels (Supplementary Fig. S3).
The CD26−/low subpopulation of γδ-T lymphocytes is augmented in non-allergic compared to 
allergic asthmatics. To ascertain the specific lymphocyte subset within the CD4− compartment show-
ing altered proportions in NAA compared to AA and to limit possible cofounding effects (e.g. age, gender), we 
analysed blood samples from a second cohort study limited to AA and NAA donors (n = 12/each) with sim-
ilar age and M/F proportions. The new analysis focused on CD8+ T (CD3+CD8+), NK (CD3−CD56+), NKT 
(CD3+CD56+), B (CD19+), and γδ-T cells (TCRγδ+CD3+) (Supplementary Fig. S4). There was no evidence for 
expansion of these circulating populations in NAA. However, this new study revealed an increased proportion of 
CD26−/low γδ-T lymphocytes (and an opposite pattern for CD26high γδ-T cells) in NAA compared to AA (Fig. 4). 
Once again, the percentage of γδ-T cells correlated inversely with the percentage of CD26+ cells within this subset 
(rs = −0.460, P = 0.024). Interestingly, there was also a negative correlation between the percentages of γδ-T cells 
and B lymphocytes (rs = −0.602, P = 0.002).
CD26 could act as a negative regulator of T-cell proliferation. CD26 down-modulation on T lym-
phocytes from both AA (CD4+ T cells) and NAA (CD4− γδ-T cells) patients could be: a) a consequence of differ-
ent mechanisms that simply reduce the amount of this protein on the cell surface, like, for example, the dilution 
of CD26 molecules (half-life > 48 h) throughout the successive cytokinesis rounds; or b) a necessary condition 
to initiate the proliferation/differentiation programme of naïve or memory T cells. To distinguish between both 
possibilities, we tested the effect of RNA interference (RNAi) on the DPP4 gene during the proliferative response 
of T lymphocytes to mitogenic triggers. Peripheral blood mononuclear cells (PBMCs) were CFSE-labelled and 
cultured in vitro with either non-target or CD26/DPP4-specific Accell siRNAs. As CD26 up-regulation during T 
cell activation was mainly derived from the translocation of this protein from intracellular stores toward the cell 
Figure 3. CD4− lymphocytes with a highly differentiated memory phenotype are expanded in non-allergic 
asthma. (a) CD4− lymphocytes were identified by flow cytometry (left and middle dot plots). Then CD127 and 
CD26 were used to identify five subsets within the CD4− lymphocyte compartment (right dot plot).  
(b) Percentage of CD4−CD26+ or CD4−CD126+ cells from healthy controls (HC; N = 32), rhinitis (R; N = 44), 
allergic asthma (AA; N = 100) and non-allergic asthma (NAA; N = 92). (c) Percentage (median ± IQR1-3) 
of CD26−CD127−, CD26intCD127+, and CD26highCD127+ cells amongst CD4− lymphocytes in HC, R, AA, 
and NAA. (d) Composition of CD4− lymphocyte subsets based on CD3 (T), CD8 (Tc), CD19 (B), and CD56 
(NK, NKT) antigens (Data from 3 representative donors). (e) Phenotypic analysis of CD4− subsets based 
on CD45RA, CCR7, CD127, CD28, and CD27 markers (data from 3 representative donors). Statistically 
significant differences between groups are indicated (Kruskal-Wallis test: P < 0.05). In order to make the figure 
more understandable, sections (c,d and e) show only those CD4− subsets gated in (a) (right dot plot) where 
differences between groups were observed (CD26−CD127−, CD26intCD127+, and CD26highCD127+ cells).
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surface, T-cell division was stimulated with phytohemagglutinin P (PHA) in the presence or absence of IL-12, 
a cytokine that promotes CD26 mRNA translation. Furthermore, it was required to extend the in vitro culture 
incubation for 6 days to observe the inhibitory effect of the CD26-specific siRNA on protein levels. As expected, 
CD26-specific siRNAs down-modulated the expression of CD26, but only in IL-12-stimulated PBMCs (Fig. 5a). 
After verification of compliance with CD26 down-modulation by RNAi, we estimated the percentage of cells 
that divided at least once. As Fig. 5b shows, those T cells where DPP4 gene silencing was more intense (i.e. 
IL-12-costimulated) were the ones showing an increase in the proliferation rate.
CD126/IL-6Rα down-modulation in neutrophils, monocytes, and lymphocytes is associated 
to disease severity and asthma control. Asthma severity could be responsible for changes in pulmo-
nary and inflammatory parameters. To assess this, we segregated asthma patients into moderate-severe (n = 90) 
and intermittent-mild (n = 102) asthmatics; asthma control degree was also considered (Table 1). As expected, 
FEV1 and FEV1/FVC were decreased in moderate-severe and uncontrolled asthmatics (Supplementary Table S2), 
regardless of phenotype. Eosinophils count was also augmented in moderate-severe and badly-controlled asth-
matics (Supplementary Table S2), although the statistical significance is only maintained in AA after segregation 
according to the phenotype. In contrast, badly-controlled NAA was only characterized by an increased neutro-
phils count (P = 0.032; data not shown). Interestingly, there was a decrease in the expression of CD126 in many 
leukocyte subsets (monocytes, neutrophils, CD4− and CD4+ lymphocytes) as the severity was higher (Fig. 6). 
This finding extends to Teff, Treg, and Tlow lymphocytes. Similar decreased levels were obtained for CD126 
on leukocytes from badly-controlled asthmatics. Furthermore, we did not observe changes in CD26 levels on 
most leukocyte subpopulations with asthma severity, although the percentage of CD26+ Tregs was higher in 
moderate-severe NAA patients (Supplementary Fig. S5). Finally, the percentage of CD4+ lymphocytes was higher 
in badly-controlled AA (P = 0.006; data not shown).
Discussion
This study shows an intense correlation between the expressions of CD26/DPP4 and CD126/IL-6Rα, two mole-
cules that identify naïve (CD26int and/or CD126+ cells), memory (CD26high and/or CD126+), and highly differen-
tiated effector subsets (TEM and TEMRA cells; CD26−/low and/or CD126−). Precisely, the last subset is expanded in 
both groups of asthma patients: AA (CD4+ Tlow cells) and NAA (γδ-T cells). Probably as a result of this expan-
sion, there is a reduction of sCD26 concentration in plasma that is shared by AA and NAA patients. Moreover, 
Figure 4. Non-allergic asthmatics exhibit augmented proportions of CD26−/low γδ-T lymphocytes compared 
with allergic asthmatics. (a) Gating strategy for CD3+γδ-TCR+ lymphocytes (γδ-T cells). After gating, 
expression of CD127 and CD26 was used to identify three subsets (CD26−/lowCD127−/+, CD26intCD127+, and 
CD26highCD127+) in γδ-T cells (right dot plot). (b–d) Percentage (median ± IQR1-3) of CD26−/lowCD127−/+ 
(b), CD26intCD127+ (c), and CD26highCD127+ cells (d) amongst γδ-T lymphocytes in allergic (AA; N = 12) and 
non-allergic (NAA; N = 12) asthmatics. Statistically significant differences between these two groups of donors 
are indicated (t-test: P < 0.05).
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CD26 could be relevant to slow the rate of cell division of naïve or central-memory T lymphocytes and, con-
versely, its down-modulation necessary for rapid proliferation and differentiation into effector cells. Finally, 
down-regulation of CD126 on leukocytes may be related to asthma severity.
CD26 is an activation marker18 that identifies TH1 and especially TH17 cells11. Our results show an increase 
of “activated” CD4+ cells (CD26+) in asthma, in agreement with published work19. Despite the IL-13-dependent 
up-regulation of CD26/DPP4 on human bronchial epithelial cells43 or the potential role of TH17 cells in NAA8,44, 
both AA and NAA patients express similar levels of CD26 on CD4+ T cells. A possible explanation for this 
observation is that following antigen presentation to naïve CD4+ T cells in lymph nodes, these lymphocytes 
proliferate, differentiate, and move back to the peripheral circulation, where they still have an early differenti-
ation state (CD26high; TH17 ≫ TH1 > TH2) and an extended half-life compared to innate leukocytes (CD26−/low; 
eosinophils, neutrophils) (Supplementary Table S3). Therefore, these circulating TH cells will still require the 
down-modulation of CD26 to become TEM/TEMRA cells and migrate into sites of inflammation; a similar event 
would occur with IL-6Rα/CD126 on T lymphocytes to favour the proinflammatory trans-signalling pathway.
Three major TH subsets coexist in circulation: Treg (CD25highCD26lowCD127low), “conventional” Teff 
(CD25lowCD26highCD127high), and Tlow cells (CD25−/lowCD26−/lowCD127−/low). The latter is a highly differentiated 
counterpart of “conventional” Teff cells. CD4+ Tlow cells are expanded in AA20 and their abundance is negatively 
correlated with CD26/CD126 levels, as it happens for other subpopulations (e.g. CD26−/low γδ-T lymphocytes). 
Despite the small expansion of the Tlow cell compartment, this might be relevant for AA pathogenesis consider-
ing two facts: (a) total lymphocytes, instead of antigen-specific cells, have been measured; and (b) patients were in 
stable phase (i.e. absence of exacerbations for 4 weeks before sample collection). On the other hand, even though 
there is a negative association between the percentage of CD26+/CD126+ cells and the percentage of Tlow cells, 
this does not necessarily imply CD26-dependent causation. Therefore, we performed T cell proliferation assays 
after siRNA-mediated depletion of CD26 mRNA. These results show a negative regulatory role for CD26 in T 
cell proliferation15. Thus, our data agree with the study of Yan et al. working with ovalbumin-induced CD26−/− 
C56BL/6 animals45, or Stephan et al. showing that oral administration of DPP4-inhibitors aggravates the airway 
inflammation in a rat model of asthma46.
A reduced expression of CD27, CD28, and CCR7 is the hallmark of highly-differentiated effector cells (TEM 
or TEMRA). Tlow cells fulfil these criteria; therefore, these lymphocytes might be part of a pool of “conventional” 
Figure 5. siRNA mediated depletion of CD26 mRNA leads to enhanced T-cell proliferation. PBMCs from 
healthy subjects were isolated and placed in culture for 6 days in 96 round-well plates. To promote T-cell 
division, Accell culture medium was supplemented with PHA ± IL-12. Besides, a CD26-specific or a non-
targeting Accell siRNAs pool was also used. (a) Expression of CD26 (MFI; mean fluorescence intensity) on 
PBMCs was assessed by flow cytometry. Three representative assays are shown. 2-way ANOVA with Tukey’s 
multiple comparison test: *P < 0.05, ***P < 0.001, ****P < 0.0001; n.s., non-significant. (b) PBMCs from 2 
representative donors were labelled with CFSE and T-cell proliferation induced by PHA ± IL-12 was assessed by 
CFSE-dilution assays. Responder frequency is the percentage of T lymphocytes that divided at least once. 2-way 
ANOVA with Tukey’s multiple comparison test: *P < 0.05, **P < 0.01, ****P < 0.0001; n.s., non-significant.
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CD4+ Teff cells that remains upon antigen clearance and develop into senescent lymphocytes with short tel-
omeres, low proliferative capacity, and presence of cytotoxic molecules47. Thus, in line with other works17,28, 
expression of CD26/DPP4 and CD126/IL-6Rα would identify cells with a naïve (CD45RA+, CD62L+, CCR7+) 
or a central-memory (CD45RO+, CD62L+, CCR7+) phenotype, while reduced levels would distinguish CD4+ 
T subsets expanded in AA with an TEM or TEMRA phenotype. Similarly, we found augmented proportions of 
peripheral blood CD4− γδ-T cells with a CD26−CD126−CD127− phenotype (likely V𝛿2/Vγ9+)48 in NAA 
compared to AA. Several studies have described the presence of different circulating V𝛿2/Vγ9+ T cells (naïve/
CD45RA+CD27+, TCM/CD45RA−CD27+, TEM/CD45RA−CD27−, and TEMRA/CD45RA+CD27−)49,50, which is 
compatible with the existence of CD26− (TEM/TEMRA), CD26int (naïve), and CD26high (TCM) γδ-T subsets. Thus, 
an enlarged population of CD26− γδ-T lymphocytes (i.e. TEM/TEMRA) with a preferential production of TH17 or 
TH1 cytokines51 in NAA patients could explain the enhanced airway inflammation and the inverse relation-
ship between γδ-T cell and B-cell proportions. However, it has been previously reported that most of circulating 
γδ-T cells are CD126−gp130− (i.e. they are not IL-6-responders)52, which raises the question about how they can 
become IL-17-producers.
Another caveat is if those phenotypic changes on T lymphocytes could be mirrored in serum samples. 
Different circulating molecules were measured (TGF, TNF, sCD25, sCD26) (Table 1; Fig. 1), but most of them 
remained unaltered. We did not quantify “soluble” IL-6R/CD126 (sIL-6R/sCD126), but several authors reported 
higher levels in stable asthma and especially upon flare-ups due to mechanisms involving sheddases (e.g. 
ADAM10/17)53–55, spliceosomes53,56, or vesicles54. In contrast, changes in sCD26 levels in asthma remain almost 
unexplored. Lun et al. reported an elevation of sCD26 in AA patients linked to the activated phenotype (CD26high) 
Figure 6. Generalised down-modulation of CD126 in leukocytes from patients with moderate-severe 
asthma. Monocytes (a), neutrophils (b), and lymphocytes (c,d) were gated on a flow cytometry FSC/SSC plot. 
Afterwards, lymphocytes were further subdivided into CD4− (c) and CD4+ (d) cells. The number of CD126 
antibodies bound per cell (ABC; median ± IQR1-3; see Material and Methods section) was measured on every 
population (a–d) in intermittent-mild (IMA; N = 102) and moderate-severe (MSA; N = 90) asthma patients. 
Statistically significant differences between these two groups of donors are indicated (t-test: P < 0.05).
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of CD4+ T lymphocytes19. However, reduced sCD26 levels have been recently described in severe asthmatics57 
or a low eosinophilic TH2low severe asthma endotype58. Our results are in agreement with these last works and 
support a rather generalized (AA and NAA) sCD26 down-modulation. The underlying mechanism is likely the 
expansion of CD26− T subsets20 with a TEM or TEMRA phenotype: CD4+ T cells in AA and CD4− γδ-T cells in 
NAA. Reduced levels of CD26 on lymphocytes and the extracellular compartment could be concomitant with the 
loss of caveolin-1 (a CD26 ligand) in bronchial epithelial cells and monocytes from asthmatics15. Moreover, the 
decrease of CD26 levels may be important for the bioavailability of soluble factors (e.g. chemokines, adenosine) 
and to promote cell functions like proliferation, chemotaxis, and migration toward inflamed tissues15.
Treg cell function has been described as impaired in asthma59. Although we did not find deregulation of Treg 
numbers, they showed increased CD26 expression in asthmatic patients. This is relevant because CD39 is an 
ecto-enzyme expressed by CD26− Treg lymphocytes12,60 and involved in adenosine (Ado) production61. Ado is an 
immune-regulatory molecule whose synthesis is counteracted by adenosine deaminase (ADA), an ecto-enzyme 
anchored to CD2662,63. Therefore, a CD26high phenotype in Tregs could decrease local Ado concentration and 
exacerbate disease severity64. Indeed, the percentage of CD26+ Treg cells in NAA was higher in moderate-severe 
patients than intermittent-mild subjects. The percentage of CD127+ Treg cells, a phenotype correlated with a 
diminished suppressive capacity65, was also augmented in asthmatics compared to rhinitis and HC. However, 
future studies including the assessment of Treg function in NAA and AA will be necessary.
Asthma severity is also influencing CD126 levels on CD4+ T cells, neutrophils and monocytes. IL-6 acts via 
either IL-6R (classic-signalling) or sIL-6R/sCD126 (trans-signalling)22. Contrary to the anti-inflammatory role 
of the first pathway28, the trans-signalling route allows CD126−CD130+ cells to respond to IL-627 and is impor-
tant in asthma through the maintenance of TH17 cells or the inhibition of T-cell apoptosis66. Naïve CD4+ T cells 
down-modulate IL-6R upon TCR-mediated activation, probably due to protein shedding28. This release mecha-
nism has been observed in asthma, and sIL-6R levels have been directly associated with IgE levels, but negatively 
with lung function67. Therefore, reduction of CD126 expression in monocytes, neutrophils, and CD4+ cells from 
moderate-severe patients highlights the role of IL-6 trans-signalling in asthma severity.
In conclusion, our data provide evidence that both asthma phenotypes share common immune-pathologic 
mechanisms, with expansion of CD26−/low subsets in AA (CD4+ Tlow or “highly-differentiated” Teff cells) and 
NAA (CD4− T cells; γδ-T lymphocytes) and down-modulation of additional surface molecules (IL-6Rα/CD126, 
CD27, CD28, IL-7Rα/CD127, CCR7) to produce differentiated effector subsets and extracellular sCD26 reduc-
tion. This CD26/sCD26 down-modulation and the potential role in T-cell proliferation should be considered in 
the light of clinical usage of DPP4 inhibitors and anti-CD26 antibodies.
Material and Methods
Subjects. Adult patients with asthma or allergic rhinitis were recruited from hospital consultations for 
Pneumology in Galicia (Spain) between 2014 and 2016. The diagnosis of different asthma phenotypes and allergy 
was confirmed according to Global Strategy for Asthma Management and Prevention (GINA 2006, http://www.
seicap.es/documentos/archivos/GINA2006general.pdf) criteria for at least one year prior to study initiation. A 
positive skin prick test and the presence of allergen-specific IgE were used to confirm sensitization in allergic 
patients. Lung function parameters (forced expiratory volume in the 1st second (FEV1), forced vital capacity 
(FVC), and FEV1/FVC ratio) as well as eritro-sedimentation rate (ESR) were also analysed. All asthmatics were 
in a stable phase of the disease (i.e. absence of exacerbations for at least 4 weeks before sample collection). Healthy 
donors were subjects without allergy or systemic diseases, who were scheduled for minor surgeries (orthopedic 
surgery or inguinal hernia). A second cohort of patients was also included with 12 patients with AA (M/F pro-
portion: 6/6; age: 52.75 ± 14.12) and 12 patients with NAA (M/F proportion: 6/6; age: 61.00 ± 10.71), recruited 
from hospital consultations for Pneumology in Galicia, Spain. The research project was approved by the Ethics 
Committee of Clinical Research of Galicia (2011/001), Spain, all subjects signed an informed consent, and all 
research was performed in accordance with the relevant guidelines and regulations.
Biochemical determinations. Biochemical determinations and nucleated cell counting were performed by 
using an ADVIA®1650 analyser (SIEMENS Healthcare Diagnostics S.L., Berlin, Germany) and an ADVIA®2120 
haematology counter (SIEMENS Healthcare Diagnostics S.L., Berlin, Germany), repectively. Serum TGF-β1 lev-
els were measured using ELISA plates (Human TGF-beta1 Platinum ELISA; ref. BMS249/4TEN; eBioscience) fol-
lowing commercial guidelines. Optical densities were assayed at 450 nm (Labsystem Multiscan MS), and protein 
concentration was calculated from standard curves.
Flow cytometry assays. Venous peripheral blood from each donor was collected in EDTA tubes (BD 
Vacutainer K2E). Then, FITC, PE, PE-Cy7, PerCP-Cy5.5 or AlexaFlour-647-labelled mouse IgG1 κ isotype anti-
bodies (BD Bioscience) or specific antibodies were incubated with cells for 30 min in FACS buffer (PBS, pH 
7.4, 2% FBS). We used BD FACSTM Lysing Solution (15 min; room temp.) to lyse red blood cells before sample 
collection. Finally, 200000 events were acquired on a BD FACSortTM flow cytometer and data were analysed 
using WinMDI 2.9 software (Joseph Trotter, La Jolla, CA. USA). A list of antibodies is shown in Supplementary 
Table S4. Isotype antibodies were used to determine the non-specific binding of the antibodies and therefore 
to set a threshold value to identify negative and positive populations. Single stained lymphocytes were used for 
fluorescence compensation.
Flow cytometry data are presented as either “percentage of positive cells” or “number of antibodies per cell” 
(ABC) instead of mean fluorencence intensity (MFI). We used the BD Quantibrite™ Beads PE kit (Fluorescence 
Quantitation Kit; BD Bioscience) to estimate ABC according to manufacturer instructions. In brief, we ran a BD 
Quantibrite PE tube with the same instrument settings as the assay. Therefore, MFI values in FL2 were converted 
into the number of PE molecules bound per cell. Finally, this number of PE molecules/cell was changed into ABC 
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values by using known ratios of PE to antibodies. We took advantage of this transformation to minimise as much 
as possible the inter-day variation related to the working conditions of the flow cytometer.
In vitro proliferation assays and CD26 mRNA silencing. PBMCs were placed in RPMI 1640 at a cell 
density of 107 cell/mL and incubated with 5 μM CFSE for 8 min at RT in the dark. Then, FBS was added to 
stop the reaction and cells were thoroughly washed with RPMI 1640 before cell counting. Cell cultures were 
set up at 0.25 × 106 cells/mL in 96-well microplates (round-wells). Accell delivery media (ref. B-005000-500; 
Dharmacon) was used to culture these cells under non-serum conditions. The Accell delivery medium was sup-
plemented or not with 1 μg/ml PHA (±2 ng/ml IL-12), in the presence of either DPP4-specific or non-targeting 
Accell siRNAs pools (Dharmacon). To achieve a partial gene silencing we used a commercial Accell SMART 
pool of 4 short interfering RNA (siRNA) designed to target the mRNA encoded by the human DPP4 gene (ref. 
E-004181-00-0005; Dharmacon); these siRNAs were designed to minimize the off-target effects. Besides, we also 
used two non-target siRNAs: a) an Accell green non-targeting siRNA (ref. D-001950-01-05; Dharmacon), which 
is a fluorescent unspecific siRNA used for assessment of Accell siRNA passive delivery effectiveness; b) a nega-
tive control Accell non-targeting siRNA pool of four siRNAs (ref. D-001910-10-05; Dharmacon) to control the 
background response to siRNA. All these siRNAs were initially resuspended at 100 μM by using a 1X siRNA 
buffer (ref. B-002000-UB-100; Dharmacon). Strikingly, the working concentration suggested by the manufacturer 
(1 μM) induced high cell mortality. Therefore, we titrated down the concentration of siRNA by using the Accell 
green non-targeting siRNA. A final concentration of 0.02 μM was selected to carry out the final experiments. This 
concentration was enough to label > 98% of cells and allow a high cell viability (>95%).
Upon 6 days of in vitro culture, CFSE fluorescence and the number of cell divisions were measured by flow 
cytometry (Supplementary Fig. S6), as well as the amount of CD26 protein with both specific anti-CD26 and 
isotype antibodies. Each condition was tested several times (n = 3–5 technical replicates). Unlabelled cells served 
as negative controls in cell proliferation assays. The calculated responder frequency (Rf) is the percentage of 
responder T cells that divided at least once (Supplementary Fig. S6).
Statistics. Descriptive data are presented as median (interquartile range; IQR1-3). To assess the changes 
between asthmatic groups, rhinitis, and healthy donors for non-normally distributed variables we used the 
Kruskal–Wallis test followed by Dunn’s multiple comparison test. Spearman’s test was used to measure associa-
tion between these variables. For CFSE proliferation studies, a two-way ANOVA followed by a Tukey’s multiple 
comparison test were used. Finally, t-test was performed with data from Fig. 2c to assess changes in normally dis-
tributed variables between moderate-severe allergic asthmatics and healthy subjects. Mann-Whitney U test was 
used to assess changes in non-normally distributed variables. All analyses were conducted using GraphPad Prism 
6.0 (GraphPad Software, Inc., San Jose, California, USA). The statistical significance was defined as P < 0.05.
Data Availability
The datasets analyzed are available from the corresponding author on justifiable request, and not publicly availa-
ble due to protection of participant confidentiality.
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